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Background: The objective of this study was to evaluate the comparative efficacy of indacaterol 75 μg once daily
(OD), tiotropium 18 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID, and placebo for the treatment
of chronic obstructive pulmonary disease (COPD) based on individual patient data (IPD) from randomized
controlled trials (RCTs) from the indacaterol trial program and aggregate data (AD) identified from a systematic
review of RCTs.
Methods: 22 RCTs were included in the AD analysis that evaluated: indacaterol 75 μg (n = 2 studies), indacaterol
150 μg n= 3, indacaterol 300 μg (n = 2), tiotropium 18 μg (n = 10), salmeterol 50 μg (n = 6), and formoterol 12 μg
(n = 4). All of the studies except for one head-to-head comparison (tiotropium vs. salmeterol) were placebo
controlled. Outcomes of interest were trough forced expiratory volume in 1 second (FEV1) and St. George’s
Respiratory Questionnaire (SGRQ) total score at week 12. The AD from all trials was analysed simultaneously using a
Bayesian network meta-analysis (NMA) and relative treatment effects between all regimens were obtained. In a
separate analysis, the IPD available from the 6 indacaterol RCTs was analysed in a NMA. Treatment-by-covariate
interactions were included in both analyses to improve similarity of the trials.
Results: All interventions compared were more efficacious than placebo regarding FEV1 at 12 weeks. Indacaterol
75 μg is expected to result in a comparable FEV1 at 12 weeks to tiotropium and salmeterol based on both IPD and
AD analyses. In comparison to formoterol, the IPD and AD results indicate indacaterol 75 μg is more efficacious
(IPD = 0.07 L difference; 95%Credible Interval (CrI) 0.02 to 0.11; AD = 0.05 L difference; 95%CrI 0.01; 0.09). In terms of
SGRQ total score at 12 weeks, indacaterol 75 μg and formoterol were more efficacious than placebo, whereas for
tiotropium and salmeterol the credible intervals included zero for the AD results only (tiotropium: -2.99 points
improvement versus placebo; 95%CrI −6.48 to 0.43; salmeterol:-2.52; 95%CrI: -5.34; 0.44). Both IPD and AD results
suggest that indacaterol 75 μg is expected to be comparable to all active treatments.
Conclusions: Based on a synthesis of currently available AD RCT evidence as well as an IPD network meta-analysis
of six RCTs, indacaterol 75 μg is expected to be at least as efficacious as formoterol and comparable to tiotropium
and salmeterol regarding FEV1. Furthermore, indacaterol 75 μg shows comparable level of improvement in health-
related quality of life to tiotropium, salmeterol, and formoterol, as measured by the SGRQ.* Correspondence: jjansen@mapigroup.com
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Chronic obstructive pulmonary disease (COPD) is a lung
disease characterized by airflow limitation which is not
fully reversible, involving breathlessness, decreased exer-
cise capacity, and in some cases chronic cough as well as
sputum production. Given the progressive nature of the
disease, the aim of treatments is to reduce symptoms
and exacerbations, thereby improving health-related
quality of life. Initially patients are recommended to re-
ceive a short-acting bronchodilator (i.e. salbuterol). Once
the disease progresses regular treatment with one or
more long-acting β2-agonists (LABA) (i.e. indacaterol,
salmeterol, or formoterol) or long acting anticholinergic
(LAMA) (i.e. tiotropium) is recommended [1].
Indacaterol is a novel once-daily (OD) treatment that
provides fast-acting and sustained bronchodilation for
patients with moderate to severe COPD. In the United
States indacaterol 75 μg has recently been approved by
the Food and Drug Administration as a long-term main-
tenance treatment of airflow obstruction in moderate to
severe COPD, while indacaterol 150 μg and 300 μg were
approved in 2010 by the European Medicines Agency.
Currently there is no randomized clinical trial (RCT)
that simultaneously compares all the recommended
long-acting maintenance monotherapy treatments.
Therefore, in the absence of such an RCT, there is a
need for a network meta-analysis to assess the compara-
tive efficacy of indacaterol 75 μg versus tiotropium, sal-
meterol, and formoterol.
Although mixed treatment comparisons have been
published in the area of COPD [2,3], recent studies
evaluating indacaterol have not been captured. More-
over, previous analyses relied on study-level or aggregate
level data (AD). Since randomization of patients does
not hold across trials in a network of RCTs, there might
be an imbalance in study and patient characteristics
across comparisons possibly causing biased treatment ef-
fect estimates. However, with AD one cannot separate
within-study associations from across-study associations,
and network meta-analysis with AD might be prone to
residual confounding bias due to differences in patient
characteristics across comparisons [4,5]. In contrast, the
current study also includes a network-meta analysis in-
corporating individual patient data (IPD) from the inda-
caterol trial program, which allows for meta-regression
models to accurately assess heterogeneity due to patient
characteristics with adequate power [4,5]. The IPD net-
work meta-analysis is based on six studies from an ex-
tensive clinical trial program, including the following
trials: B23354 [6], B2355 [7], INVOLVE [8], INHANCE
[9], INLIGHT-2 [10], INLIGHT-1 [11]. Results of this
analysis are also compared with an AD analysis, which
incorporates study-level evidence identified from a sys-
tematic review.The objective of the current study was to estimate the
comparative efficacy of indacaterol 75 μg OD, tiotro-
pium 18 μg OD, salmeterol 50 μg twice daily (BID), for-
moterol 12 μg BID, and placebo in terms of trough
forced expiratory volume in 1 second (FEV1) and St.
George’s Respiratory Questionnaire (SGRQ) total score.
Methods
Evidence base
A systematic literature review was performed in order to
identify RCTs evaluating the efficacy of indacaterol
75 μg, 150 μg, 300 μg, tiotropium 18 μg, salmeterol
50 μg, and formoterol 12 μg for COPD. MEDLINEW and
EMBASEW databases were searched simultaneously for
the period of 1989 to 2010. The search strategy has been
previously published [12], which includes search terms
involving a combination of free-text and thesaurus terms
relevant to COPD, indacaterol, salmeterol, formoterol,
tiotropium, and RCTs. The relevance of each citation
identified from the databases was based on title and ab-
stract according to predefined selection criteria. Study
selection criteria in terms of population, outcomes and
study design were defined and dictated which articles
were selected:
Population: Adults with COPD.
Interventions: Indacaterol 75/150/300 μg OD, tiotro-
pium 18 μg OD, salmeterol 50 μg BID, and formoterol
12 μg BID.
Comparators: Comparators included any of the inter-
ventions or placebo.
Outcomes: Trough FEV1 and SGRQ total score.
Study Design: RCTs.
Additionally, any unpublished studies in the indaca-
terol trial program that evaluated indacaterol 75 μg at
12 weeks were included. Studies within the program
based on an Asian population were excluded, as were
unpublished supplementary trials. Individual patient data
(IPD) was available from the indacaterol RCTs that
formed the evidence network for the network meta-
analysis (B2354 B23354 [6], B2355 [7], INVOLVE [8],
INHANCE [9], INLIGHT-2 [10], INLIGHT-1 [11]).
Please note that data for indacaterol 150 and 300 μg was
included in the evidence base, although results are not
presented for these doses as it was not considered rele-
vant for the current decision problem. Data for indaca-
terol 600 μg was available from the INVOLVE study
which was excluded from the evidence base as this dose
is not approved.
For the abstracts that potentially met these criteria,
publications were obtained if available. Based on these
full text reports, two reviewers evaluated whether each
study met the selection criteria. Information was
extracted relating to the study design, population charac-
teristics, interventions, and the outcomes of interest at
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(CFB) or least square mean outcome at follow-up was
extracted for each outcome of interest or was calcu-
lated as the difference between the CFB (or least
square mean at follow-up) for the active and placebo
treatments. If necessary, the outcomes of interest were
extracted from Figures using DigitizIt software version
1.5.8. The standard error of the difference in CFB was
extracted where available or calculated based on the
available uncertainty estimates reported. The standard
error of the difference was imputed where necessary
based on the average standard deviation across the
included studies and combined with the study-specific
sample size.
Outcomes of interest
The outcomes of interest were: FEV1 at 24 hrs post-dose
(‘trough’; mean of the values assessed at 23 h 10 min
and 23 h 45 min following the previous morning dose),
and health status as assessed by the SGRQ total score at
12 weeks. FEV1 was selected as it represented the pri-
mary outcome in all six indacaterol trials, while SGRQ
total score reflects a patient reported outcome measured
by a validated instrument.
Analysis
For each of the endpoints of interest a Bayesian network
meta-analysis was performed [13,14] in two separate
analyses using 1) IPD from the indacaterol studies and
2) AD from all studies. Analyses within the Bayesian
framework involve data, a likelihood distribution, para-
meters, a model, and a prior distribution [15]. The
model relates the data from the individual studies to the
basic parameters in order to estimate the relative treat-
ment effects of each intervention compared to placebo
[16]. The relative efficacy estimates between all the inter-
ventions can be calculated as a function of the basic
parameters for each intervention [16].
In order to minimize confounding bias, treatment-by-
covariate interactions were incorporated in the models
[17]. Potential effect modifiers were selected based on
clinical expertise. Therefore, in addition to treatment
and study effects, the final models analysed the outcome
at 12 weeks including covariates and treatment by cov-
ariate interactions. The IPD analysis included the follow-
ing covariates: baseline value of outcome, proportion of
current smokers (as opposed to ex-smokers), reversibil-
ity to short-acting β2-agonists, and reversibility to short-
acting anticholinergic. Since reversibility data was not
consistently reported at the study level, the following
covariates were included in the AD analysis: proportion
of current smokers, proportion of patients with severe
or very severe COPD (as opposed to mild or moderate
COPD) based on the GOLD guidelines; average age, andproportion of males. In the case of the AD analyses, the
CFB was analysed and therefore the baseline values of
the outcomes were not included as covariates as was
done for the IPD, where the outcome at 12 weeks
follow-up was analyzed. Analyses without adjustment for
covariates were also performed.
Linear models with normal likelihood distributions
were used. To minimize the influence of prior beliefs on
the analysis, all model parameters were estimated using
non-informative prior distributions. Sensitivity analyses
were performed on the prior distribution by varying the
level of precision. The deviance information criterion
(DIC), which provides a measure of model fit that pena-
lizes model complexity, was used to select fixed effects
models over random effects models [15,18,19].
All models were analyzed using Markov Chain
Monte Carlo techniques (MCMC) with WinBUGS
1.4.1. The IPD was programmed using R (Version
2.8.1). For each analysis the Gelman-Rubin statistic (as
modified by Brooks and Gelman [20]) was visually
inspected based on a graphical plot of the starting iter-
ation of each range illustrating the approximate point
of convergence. The posterior distribution for the rela-
tive efficacy of indacaterol 75 μg compared to the
treatment alternatives (i.e. difference in FEV1 or SGRQ
total score) were summarized with the median as
measure of the point estimate and the 2.5th and
97.5th percentile to reflect the 95% Credible Interval
(CrI). 95% CrIs represent the 95% probability that the
true underlying effect lies in the interval specified. The
probability that indacaterol 75 μg was better than the
alternatives is also presented.
Results
Study and patient characteristics
The study selection process is summarized in Figure 1.
The literature search identified 411 potentially relevant
studies. The first review excluded 331 (81%) of poten-
tially relevant studies which did not meet selection cri-
teria. The reasons for exclusion were related to the
following factors: trial design – 89 (22%), trial duration
was less than or equal to 6 weeks – 81 (20%), interven-
tion – 50 (12%), duplication – 56 (14%), comparator –
38 (9%), and population – 17 (4%). The full text review
of 80 remaining studies excluded 62 (15%) studies for
reasons including outcomes– 22 (5%), intervention dose
out of scope– 15 (4%), study design – 11 (3%), trial dur-
ation– 8 (2%), intervention– 3 (1%), population– 1
(<1%), and duplication– 2 (<1%). Overall, 18 publica-
tions were identified from the search of the databases,
which included two indacaterol publications by Dahl
et al. 2010 for study B2334 and by Feldman et al. 2010
for study B2346. Two additional RCTs assessing indaca-
terol 75 μg were provided by Novartis (clinical trial
Figure 1 Flow Diagram of study selection.
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ating indacaterol 150 and 300 μg which were published
at the time of the analysis (B2335S by Donohue, 2010;
B2336 by Kornmann 2010). Therefore, overall thereA.     Individual patient data network
Figure 2 Network of evidence.1Note: Two 3-arm trials and one 4-arm trialwere 6 indacaterol studies included. In total, 22 RCTs
were included in the AD analysis [21–36].
In Figure 2 the network of RCTs is presented. Figure 2A
illustrates the trials where IPD was available and Figure 2BB.         Aggregate data network1
were included and counted separately; therefore totals do not sum to 22.
Table 1 Key study characteristics for all studies
Source Trial Design1 Arm 1 Centres/Countries2 Inclusion criteria3 Background treatment
allowed4
Background treatment not allowed4
MOITA, 2008 12 week RCT,
PC, DB, MC
Tiotropium; 18 μg;
OD(n = 147) vs.
Placebo (n = 164)
31 centres/ Portugal FEV1≤ 70 %; FEV1/FVC≤ 70 %;
excluded if≥ 3 exacerbations
previous year
LABAs, theophylline, muco cs,
ICS, stable doses oral cortic teroids.
Temporary increases in the hylline
or oral steroids for exacerb ns






OD (n= 46) vs.
Placebo (n = 54)
10 centres/ France FEV1≤ 50 %; FEV1/SVC≤ 70 %;
residual volume≥ 125 %;
excluded if unstable doses
oral corticosteroid 6 wks prior
Stable doses oral corticoste ids,
ICS, theophylline preparatio ,
mucolytic agents






OD (n= 100) vs.
Placebo (n = 96)
12 centres/ USA FEV1≤ 60 %; FEV1/FVC≤ 70 %;
excluded if exacerbation in
prior 6 wks







O (n = 279) vs.
Placebo (n = 191)
25 centres/ USA FEV1≤ 65 %; FEV1/FVC≤ 70 % Stable doses of theophyllin
ICS, oral prednisone







OD (n= 550) vs.
Placebo (n = 371)








OD (n= 914) vs.
Placebo (n = 915)
26 centers/ USA FEV1≤ 60 %; FEV1/FVC≤ 70 %;
excluded if not recovered from
exacerbation≥ 30 days prior
All other respiratory medic ns
(including ICS and LABAs)
Open-label anticholinergic
bronchodilator
CHAN, 2007 48 week RCT,
PC, DB, MC
Tiotropium; 18 μg,
OD (n= 608) vs.
Placebo (n = 305)
101 centers/ Canada FEV1≤ 65 %; FEV1/FVC≤ 70 %;
included if≥ 1 exacerbation
previous year but not in
6 weeks prior
Stable dose oral corticoster s,
ICS, theophylline preparatio ,
mucolytic preparations








OD (n= 266) vs.
Placebo (n = 288)
123 centers/ France FEV1 20-70 %; FEV1/FVC≤ 70 %; Stable doses of theophyllin









BID (n = 177) vs.
Placebo (n = 185)
76 centres/ USA FEV1 >40 % and <65 %;
FEV1/FVC< 70 %; symptoms
criteria; excluded if oral
corticosteroids 6 wks prior





PC, DB, MC, DD
Salmeterol; 50 μg;
BID (n = 160) vs.
Placebo (n = 181)
65 centers/ countries NR FEV1 <65 % but >70 L. FEV1/FVC
≤70 %; excluded if moderate
or severe exacerbation during run-in





PC, DB, MC, DD
Salmeterol; 50 μg;
BID (n = 47) vs.
Placebo (n = 50)
3 centers/ Netherlands FEV1 ≥40 % and ≤65 %;
FEV1/FVC< 60 % (post
salbutamol); symptoms criteria;
Stable doses of maintenan
drugs
NR
CELLI, 2003 12 week RCT,
PC, DB, MC, DD
Salmeterol; 50 μg;
BID (n = 554) vs.
Placebo (n = 271)
189 centres/
15 countries
FEV1 20-70 %; FEV1/FVC< 65 %;
<15 % reversibility FEV1; symptom
criteria; excluded if exacerbation
6 wks prior










































Table 1 Key study characteristics for all studies (Continued)
GROSS, 2008 12 week RCT,
PC, DB, DD, MC
Formoterol; 12 μg;
BID (n = 114) vs.
Placebo (n = 114)
38 centres/ USA FEV1 >30 %; FEV1/FVC< 70 %;
symptom criteria; excluded if
exacerbation in 4 wks prior
Stable doses of inhaled o
oral corticosteroids
NR
ROSSI, 2002 12 month RCT,
PC,DB,MC
Formoterol; 12 μg;
BID (n = 211) vs.
Placebo (n = 220)
81 centers worldwide FEV1< 70 % of the predicted
value and≥ 0.75 L, FEV1 vital
capacity ratio of <88 % of that
predicted in men and <89 %
in women.
Inhaled salbutamol
(100 microgram per puff)
equivalent doses of albut
in US centers as needed
NR
DAHL, 2001 12 week RCT,
PC, DB, DD, MC
Formoterol 12 μg;
BID (n = 194) vs.
Placebo (n = 200)
57 centres/ Europe,
Russia, Canada, USA
FEV1 <70 %; FEV1/FVC< 88 %
for men and <89 % for women;
symptom criteria; excluded
if used oral corticosteroids
4 wks prior
Stable ICS, short courses
of antibiotics, oral cortico ids,
and/or oxygen in case of
exacerbation or respirator ection
NR
BRIGGS, 2005 12 week RCT,
DB, MC
Tiotropium 18 μg;
OD (n = 328) vs.
Salmeterol; 50 μg;
BID (n = 325)
50 centres/ Europe,
UK and USA
FEV1≤ 60 %; FEV1/FVC≤ 70 %;
excluded if exacerbation
4 wks prior






PC, DB, MC, DD
Indacaterol; 300 μg;
OD (n = 437) vs.
Formoterol; 12 μg;
BID (n = 435) vs.
Placebo (n = 432)
# centres NR/ 25
countries in S. America,
Europe, Russia, Africa,
and Asia
FEV1≥ 30 % and <80 %;
FEV1/FVC< 70 %; reversible
and non-reversible patients
included; excluded if hospitalisation
6 wks prior to trial or during
run-in period
ICS monotherapy Tiotropium, short acting
anti-cholinergics, fixed combinations
of β2-agonists and ICS or β
2-agonists and inhaled anticholinergics,
LABAs, and other SABAs, theophylline,













OD (n = 420) vs.
Indacaterol; 300 μg;
OD (n = 418) vs.
Tiotropium; 18 μg;
OD (n = 410) vs.
Placebo (n = 425)
# centres NR/ Argentina,
Canada, Europe, India,
Italy, Korea, Taiwan, USA
FEV1≥ 30 % and <80 %;




ICS monotherapy Tiotropium, short acting anti-cholinergics,
fixed combinations of β2-agonists and
ICS or β 2-agonists and inhaled
anticholinergics, LABAs, and other
SABAs, theophylline, other xanthines,






PC, DB, MC, DD
Indacaterol; 150 μg;
OD (n = 333) vs.
Salmeterol; 50 μg;
BID (n = 334) vs.
Placebo (n = 335)




FEV1≥ 30 % and <80 %;
FEV1/FVC< 70 %; reversible
and non-reversible patients
included; excluded if
hospitalisation 6 wks prior
ICS monotherapy Tiotropium, short acting anti-cholinergics,
fixed combinations of β2-agonists + ICS
or β 2- agonists + inhaled
anticholinergics, LABAs, theophylline,







PC, DB, MC, DD
Indacaterol; 150 μg;
OD (n = 211) vs.
Placebo (n = 205)
# centres NR/ USA,
Australia/ New Zealand,
Belgium
FEV1≥ 30 % and <80 %;
FEV1/FVC< 70 %; reversible
and non-reversible patients
included; excluded if
hospitalisation 6 wks prior
ICS monotherapy Tiotropium, short acting anti-cholinergics,
fixed combinations of β2-agonists and
ICS or β 2-agonists and inhaled
anticholinergics, LABAs, and other
SABAs, theophylline, other xanthines,
parenteral or oral corticosteroids
B2354, 2010 12 week RCT,
PC, DB, MC
Indacaterol; 75 μg;
OD (n = 163) vs.
Placebo (n = 160)
# centres NR/ USA FEV1≥ 30 % and <80 %;
FEV1/FVC< 70 %; Excluded
if exacerbation in 6 wks prior
Antibiotics or oral cortico ids




























Table 1 Key study characteristics for all studies (Continued)
B2355, 2010 12 week RCT,
PC, DB, MC
Indacaterol; 75 μg;
OD (n = 159) vs.
Placebo (n = 159)
# centres NR/ USA FEV1≥ 30 % and <80 %;
FEV1/FVC< 70 %; Excluded
if exacerbation in 6 wks prior
Antibiotics or oral corticosteroids
for exacerbation; ICS monotherapy
LABAs; anticholinergic
1RCT = randomized clinical trial; PC = placebo-controlled; DB = double-blind; MC=multi-centre; DD=Double dummy; NR = not reported; 2UK =United Kingdom; USA =United Sates of America; S. America = South







































MOITA, 2008 Tiotropium; 18 μg; OD NR NR 28 % NR NR NR NR
Placebo NR NR 25 % NR NR NR NR
VERKINDRE, 2006 Tiotropium; 18 μg; OD 94 % 61 (9.5) 24 % 95 % NR 1.05 (0.4) NR
Placebo 94 % 60 (10.2) 33 % 94 % NR 1.08 (0.3) NR
COVELLI, 2005 Tiotropium; 18 μg; OD 66 % 66 (8.9) 40 % 77 % 54 % 1.06 (0.4) NR
Placebo 49 % 63 (9.2) 37 % 80 % 58 % 0.99 (0.4) NR
CASABURI, 2000 Tiotropium; 18 μg; OD 67 % 65 (8.6) NR 79 % NR 1.04 (0.4) NR
Placebo 63 % 66 (9.0) NR 80 % NR 1.00 (0.4) NR
CASABURI, 2002 Tiotropium; 18 μg; OD 67 % 65 (9.0) NR 79 % 44 % 1.04 (0.4) NR
Placebo 63 % 65 (9.0) NR 80 % 40 % 1.00 (0.4) NR
NIEWOEHNER,
2005
Tiotropium; 18 μg; OD 98 % 68 (8.7) 29 % 87 % 61 % 1.04 (0.4) NR
Placebo 99 % 68 (8.5) 30 % 87 % 58 % 1.04 (0.4) NR
CHAN, 2007 Tiotropium; 18 μg, OD 59 % 68 (8.7) 32 % 79 % 66 % 0.97 (0.4) NR
Placebo 61 % 67 (9.1) 30 % 78 % 71 % 0.96 (0.4) NR
TONNEL, 2008 Tiotropium; 18 μg: OD 87 % 65 (9.7) 24 % 58 % 38 % 1.38 (0.4) NR
Placebo 85 % 64 (10.1) 30 % 62 % 36 % 1.35 (0.5) NR
HANANIA, 2003 Salmeterol; 50 μg; BID 58 % 64 (42–87) 51 % 75 % 0 % 1.25 (0.4) NR
Placebo 68 % 65 (40–81) 47 % 75 % 0 % 1.29 (0.4) NR
MAHLER, 2002 Salmeterol; 50 μg; BID 64 % 64 (40–84) 46 % NR 31 % 1.23 (NR) NR
Placebo 75 % 64 (44–90) 54 % NR 18 % 1.31 (NR) NR
VAN RUTTEN, 1999 Salmeterol; 50 μg; BID 89 % 65 (5.8) NR 73 % 81 % 1.30 (0.4) NR
Placebo 86 % 63 (7.4) NR 77 % 76 % 1.30 (0.4) NR
CELLI, 2003 Salmeterol; 50 μg; BID 80 % 64 (8.7) NR 73 % NR 1.30 (0.5) NR
Placebo 71 % 65 (8.7) NR 69 % NR 1.35 (0.5) NR
GROSS, 2008 Formoterol; 12 μg; BID 54 % 63 (9.4) 54 % 70 % 23 % 1.30 (0.4) 15 % (NR)
Placebo 57 % 64 (9.2) 54 % 64 % 19 % 1.36 (0.5) 11 % (NR)
ROSSI, 2002 Formoterol; 12 μg; BID 87 % 63 (NR) NR NR NR 1.36 (NR) NR
Placebo 80 % 63 (NR) NR NR NR 1.40 (NR) NR
DAHL, 2001 Formoterol; 12 μg; BID 74 % 64 (8.8) 46 % 63 % 47 % 1.33 (0.5) NR
Placebo 79 % 63 (9.0) 49 % 68 % 54 % 1.29 (0.4) NR
BRIGGS, 2005 Tiotropium; 18 μg; OD 65 % 64 (8.6) 35 % 86 % 54 % 1.05 (0.4) 14 % (NR)





80 % 64 (8.6) 42 % 46 % 56 % 1.48 (0.5) 12 % (13 %)
Formoterol; 12 μg; BID 80 % 64 (8.5) 41 % 44 % 51 % 1.50 (0.5) 12 % (13 %)





62 % 63 (9.4) 45 % 38 % 38 % 1.52 (0.5) 16 % (15 %)
Indacaterol; 300 μg;
OD
63 % 63 (9.3) 45 % 38 % 37 % 1.53 (0.5) 15 % (15 %)
Tiotropium; 18 μg; OD 65 % 64 (8.8) 45 % 43 % 35 % 1.45 (0.5) 16 % (18 %)





72 % 63 (8.7) 46 % 42 % 45 % 1.48 (0.5) 12 % (15 %)
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Table 2 Key patient characteristics at baseline for all studies (Continued)
Salmeterol; 50 μg; BID 75 % 63 (9.2) 46 % 43 % 46 % 1.48 (0.5) 11 % (14 %)





51 % 63 (9.9) 51 % 40 % 29 % 1.50 (0.5) 16 % (17 %)
Placebo 54 % 63 (9.6) 53 % 38 % 34 % 1.50 (0.5) 17 % (19 %)
B2354, 2010 Indacaterol; 75 μg; OD 55 % 64 (8.3) 44 % 41 % 43 % NR 15 % (13 %)
Placebo 54 % 64 (9.4) 44 % 44 % 48 % NR 17 % (14 %)
B2355, 2010 Indacaterol; 75 μg; OD 52 % 61 (9.8) 58 % 30 % 40 % NR 18 % (17 %)
Placebo 56 % 62 (9.9) 60 % 45 % 35 % NR 16 % (14 %)
1% male = proportion of patients who were male; NR = not reported; 2Age (sd or range) = average and standard deviation or age range where reported;
SE = standard error; 3% Current smokers = proportion of patients who were current smokers as opposed to ex-smokers; 4% severe (very severe) = proportion of
patients who had severe or very severe COPD as classified by GOLD guidelines (as opposed to mild or moderate COPD); 5% on ICS = proportion of patients taking
concomitant inhaled corticosteroids during trial period; 6FEV1mean L = average forced expiratory volume in 1 second. Postbronchodilator FEV1 measured 30 min
after salbutamol 400 mg inhalation (INVOLVE, INLIGHT-1/2) or albuterol 360 mg inhalation (INHANCE); 7SABA = short-acting β2-agonis. Reversibility was calculated
as the difference between the prebronchodilator and postbronchodilator values of FEV1 (in litres) as a percentage of the prebronchodilator value.
Cope et al. BMC Pulmonary Medicine 2012, 12:29 Page 9 of 15
http://www.biomedcentral.com/1471-2466/12/29presents the network containing all studies where study
level AD was used. In the IPD network of studies B2354
and B2355 assessed indacaterol 75 μg versus placebo. The
INVOLVE study evaluated indacaterol 300 μg and 600 μg
OD compared to placebo and formoterol 12 μg BID over
52 weeks. INHANCE assessed indacaterol 150 μg and
300 μg OD compared to placebo and tiotropium 18 μg OD
over 26 weeks. INLIGHT-2 compared indacaterol 150 μg
OD to placebo as well as salmeterol 50 μg BID over
26 weeks, and INLIGHT-1 evaluated indacaterol 150 μg
OD compared to placebo over 12 weeks. When the net-
work was extended to include the AD from the studies
identified in the systematic review, 16 studies were added
to the evidence base for the comparisons of tiotropium, sal-
meterol, and formoterol versus placebo as well as one study
directly comparing tiotropium to salmeterol. The included
studies were multicentre parallel RCTs that included a pla-
cebo arm, except for the head to head study by Briggs et al.
2005. All treatments were administered in a double-blind
fashion (except for the open-label tiotropium arm in the
INHANCE study) and the studies were performed predom-
inantly in Europe and North America.
Details of trial designs and characteristics of patients
included in the studies are provided in Table 1 and Table 2.
The enrolled patients were adults with a COPD diagnosis.
Included patients were 40 years of age or older who were
most often required to have an FEV1/Forced Vital Capacity
(FVC) of less than or equal to 0.70 and FEV1 percent pre-
dicted ranging from less than 80% to less than 50%. All
patients were permitted a short-acting beta-agonist as
needed, although there were some differences in other
concomitant medications allowed during the trial. For the
indacaterol trials, patients using fixed dose combinations
of β2-agonists and inhaled corticosteroids (ICS) were
switched to equivalent ICS monotherapy (at a dose and
regimen to remain consistent throughout the study). Most
studies excluded patients that had recently experienced anexacerbation or used health care resources that would sug-
gest an exacerbation (hospitalization, oral corticosteroids),
or did not report any specific exacerbation criteria. For ex-
ample, the indacaterol trials excluded patients with a
hospitalization 6 weeks prior to the trial or during run-in
period. In contrast, the study by Chan et al., 2007 required
patients to have experienced at least 1 exacerbation in the
previous year but not in the 6 weeks prior to the trial [34].
Overall, very few studies reported the exacerbation history.
The studies included a predominantly male popula-
tion, ranging from 49% to 99% (51-82% in indacaterol
trials). The average age varied from 60 years to 68 years
(61–64 years in indacaterol trials). Across the treatment
arms 24% to 60% of patients were current smokers
(40%-60% in indacaterol trials). Patients with severe or
very severe COPD per treatment arm ranged from 30%
to 95% across the treatment arms (30% to 46% in inda-
caterol trials) and the average FEV1 at baseline ranged
from 0.96 to 1.53 L (1.45 to 1.53 L in indacaterol trials)
with reversibility varying from 11 to 18 % across the
treatments where reported (11-18% range in indacaterol
trials). The ICS use depended on whether ICS was
included as a treatment arm in the study in some cases.
Therefore, the proportion of patients using concomitant
ICS varied across the studies from 0 % to 81% (29% to
56% in indacaterol trials).
Network meta-analysis
Table 3 presents the individual study summary statistics
based on the IPD for the six indacaterol studies and
Table 4 presents the study-level AD extracted for FEV1
and SGRQ. Table 5 presents the network meta-analysis
results for all of the treatments compared to placebo
with adjustment for covariates based on the IPD and AD
analyses. Table 6 presents the results for indacaterol
75 μg versus the alternative treatments using both IPD
and AD with adjustment for covariates. Results for the
Table 3 Individual patient data results for each study and treatment at baseline and 12 weeks
PLBO TIO 18 SAL 50 FOR 12 IND 300 IND 150 IND 75
FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ
B2334, 2008; N 371 347 379 359 389 372
B 1.3 43.6 1.3 44.3 1.3 44.5
sd 0.5 17.8 0.4 17.3 0.4 17.1
12 wks 1.4 41.6 1.4 39.1 1.4 38.5
sd 0.5 18.5 0.5 18.4 0.5 17.9
B2335S, 2008; N 376 347 393 374 389 375 389 368
B 1.3 45.7 1.2 44.6 1.2 44.6 1.3 45.4
sd 0.5 17.3 0.5 18.1 0.5 18.7 0.5 19.1
12 wks 1.3 42.7 1.4 41.0 1.4 39.5 1.5 39.9
sd 0.5 18.3 0.5 18.4 0.5 18.9 0.5 19.6
B2336, 2009 N 316 294 316 300 320 309
B 1.3 43.6 1.3 43.2 1.3 43.6
sd 0.5 17.8 0.5 18.5 0.5 18.7
12 wks 1.3 42.4 1.4 37.7 1.5 35.9
sd 0.5 19.6 0.5 18.5 0.6 19.4
B2346, 2008 N 189 187 201 199
B 1.3 48.7 1.3 50.1
sd 0.6 18.9 0.6 18.9
12 wks 1.4 47.6 1.5 43.9
sd 0.6 19.2 0.6 19.7
B23354, 2010 N 148 142 149 147
B 1.3 49.5 1.3 48.6
sd 0.5 17.3 0.5 18.7
12 wks 1.3 47.6 1.4 42.8
sd 0.5 17.3 0.5 18.2
B23355, 2010 N 150 145 145 148
B 1.3 50.1 1.4 51.2
sd 0.5 18.1 0.5 18.1
12 wks 1.3 49.2 1.5 46.2
sd 0.5 20.1 0.6 20.0
Mean and standard deviations (sd) presented; IND 75 OD= Indacaterol 75 μg once daily; IND 150 OD= Indacaterol 150 μg once daily; Formoterol 12 μg twice
daily; TIO 19 OD= Tiotropium 18 μg once daily; SAL 50 BID = Salmeterol 50 μg twice daily; PLB = Placebo; FEV1 = Forced expiratory volume in 1 second; SGRQ= St.
George’s Respiratory Questionnaire; TDI = Transition Dyspnea Index; L = Litres; B = Baseline; 12 wks = 12 weeks; N= sample size of data included at 12 weeks. Note:
Minor differences in the outcomes compared to the study publications are present due to missing data in the covariate values for this analysis.
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and S2 as an Additional file 1.
Forced expiratory volume in 1 second (FEV1)
All interventions compared were more efficacious than
placebo regarding FEV1 at 12 weeks in both the IPD and
AD analyses (Table 5). Indacaterol 75 μg is expected to
result in a comparable FEV1 at 12 weeks to tiotropium
and salmeterol, and higher FEV1 at 12 weeks versus for-
moterol (Table 6). The results for both IPD and AD are
similar and lead to consistent conclusions, although the
point estimate for indacaterol 75 μg versus placebo islower in the AD analysis by a difference of 0.02 L as
compared to the IPD analysis (Figure 3).
St. George’s respiratory questionnaire (SGRQ)
For SGRQ an improvement in health-related quality of
life is indicated by a decrease in the total score, where a
clinically relevant improvement involves a 4 point de-
crease from baseline [37]. All of the treatments were
more efficacious than placebo in terms of SGRQ at
12 weeks, except for tiotropium and salmeterol, where
the credible intervals in the AD analysis included zero
(tiotropium: -2.99 points improvement versus placebo;
Table 4 Aggregate data individual study results for FEV1 at 12 weeks: difference in change from baseline
PLBO TIO 18 SAL 50 FOR 12 IND 300 IND 150 IND 75
FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ FEV1 SGRQ
MOITA, 2008 diff 0 0 0.10
se 0.03
VERKINDRE, 2006 diff 0 0 0.11 −6.50
se 0.04 2.90
COVELLI, 2005 diff 0 0 0.18
se 0.04
CASABURI, 2000 diff 0 0 0.15
se 0.01
CASABURI, 2002 diff 0 0 0.13
se 0.02
NIEWOEHNER, 2005 diff 0 0 0.10
se 0.01
CHAN, 2007 diff 0 0 0.10
se 0.02
TONNEL, 2008 diff 0 0 −3.47
se 1.10
HANANIA, 2003 diff 0 0 0.10
se 0.03
MAHLER, 2002 diff 0 0 0.13
se 0.02
VAN RUTTEN, 1999 diff 0 0 −0.51
se 1.66
CELLI, 2003 diff 0 0 −2.10
se 1.28
GROSS, 2008 diff 0 0 0.08 −3.51
se 0.03 1.73
ROSSI, 2002 diff 0 0 0.04
se 0.02
DAHL, 2001 diff 0 0 −5.10
se 1.73
B2334, 2008; diff 0 0 0.07 −3.20 0.17 −3.80
se 0.02 0.90 0.02 0.90
B2335S, 2008; diff 0 0 0.14 −1.10 0.18 −2.50 0.18 −2.80
se 0.02 0.86 0.02 0.86 0.02 0.87
B2336, 2009 diff 0 0 0.11 −4.20 0.17 −6.30
se 0.02 1.01 0.02 0.99
B2346, 2008 diff 0 0 0.13 −4.75
se 0.02 1.22
B23354, 2010 diff 0 0 0.12 −3.80
se 0.02 1.21
B23355, 2010 diff 0 0 0.14 −3.60
se 0.02 1.40
BRIGGS, 2005 diff 0.02 0
se 0.02
Diff = Difference versus comparator; NR =Not reported; se = standard error.
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Table 5 Results of network meta-analysis with adjustment for covariates; treatment effects versus placebo at 12 weeks
Trough FEV1 L Difference (95%CrI) SGRQ total score Difference
1 (95%CrI)
IPD AD IPD AD
Tiotropium 18 0.13 (0.10; 0.17) 0.13 (0.12; 0.15) −1.60 (−3.18;-0.05) −2.99 (−6.48; 0.43)
Salmeterol 50 0.11 (0.07; 0.15) 0.11 (0.09; 0.13) −3.32 (−5.27;-1.37) −2.52 (−5.34; 0.44)
Formoterol 12 0.06 (0.03; 0.10) 0.06 (0.04; 0.09) −2.63 (−4.25;-0.94) −3.87 (−6.95; -1.16)
Indacaterol 75 0.13 (0.10; 0.16) 0.11 (0.08; 0.14) −3.02 (−4.87;-1.22) −4.26 (−7.83; -0.41)
1 =A decrease in SGRQ total score indicates an improvement in health-related quality of life; AD = aggregate data; CrI = 95 % Credibility Interval; FEV1 = Forced
expiratory volume in 1 second; IPD= Individual patient data; SGRQ= St. George’s Respiratory Questionnaire; IPD covariates: baseline value of outcome; % current
smokers; reversibility to short-acting β2-agonists (SABA); reversibility to short-acting anticholinergic + covariate interactions with treatments. AD covariates: %
current smokers; % severe or very severe COPD; % males; age.
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ment versus placebo; 95%CrI −5.34 to 0.44) (Table 5).
Both IPD and AD results suggest that indacaterol 75 μg
is expected to be comparable to all active treatments
(Table 6). However, in comparison to salmeterol, the AD
results for indacaterol 75 μg were more favourable
(−1.74 points; 95%CrI −6.89 to 3.54) than the IPD
results (0.28 L points; 95%CrI −2.35 to 2.97), although
there was more uncertainty associated with the AD ana-
lyses and the point estimates were within the credible
intervals of the results for alternative analysis (Figure 4).
Results for indacaterol 75 μg in comparison to tiotro-
pium and formoterol were comparable based on IPD
and AD analyses, although AD results were slightly less
favourable than the IPD results.
Discussion
The aim of this study was to assess the relative effective-
ness of indacaterol 75 μg compared to tiotropium, sal-
meterol, and formoterol in patients with moderate to
severe COPD. Based on the individual patient data and
aggregate data analyses, indacaterol 75 μg is expected to
be at least as efficacious as formoterol regarding FEV1
and comparable to tiotropium and salmeterol. Patients
receiving indacaterol 75 μg also experienced a compar-
able improvement in mean SGRQ total score to those
receiving other active treatments.
Although each of the included RCTs provides evidence
for the relative efficacy of indacaterol versus an active
comparator, none of the studies evaluating indacaterolTable 6 Results of network meta-analysis with adjustment for







Tiotropium 18 0.00 (−0.05; 0.04) 44 % −0.02 (−0.06; 0.01) 1
Salmeterol 50 0.02 (−0.03; 0.07) 79 % 0.00 (−0.04; 0.04) 5
Formoterol 12 0.07 (0.02; 0.11) >99 % 0.05 (0.01; 0.09) 9
AD= aggregate data; CrI = 95% Credibility Interval; FEV1 = Forced expiratory volume
Questionnaire; IPD covariates: baseline value of outcome; % current smokers; revers
anticholinergic + covariate interactions with treatments.AD covariates: % current sm75 μg included active comparators. Given that all studies
were connected in the network predominantly through
placebo, it was possible to indirectly compare the treat-
ments of interest in the network of evidence by synthe-
sizing the results of the RCTs by means of a Bayesian
network meta-analysis [15,18]. This framework provides
the relative effectiveness for the competing interventions
as well as the probability of being the better treatment,
which naturally supports decision-making and is intui-
tive for decision-makers [13,14]. The internal validity of
a network meta-analysis is contingent upon the extent
of confounding bias due to similarity and consistency
violations [16].
Overall, the RCTs were of high quality. A potential
limitation of the evidence base is the open-label evalu-
ation of tiotropium in the INHANCE study. Despite this
limitation, Donohue et al. [9] reported that the treat-
ment effect of tiotropium compared to placebo was
similar to previous results where tiotropium was blinded
for trough FEV1 [35,36,38]. Furthermore, results from a
blinded RCT by Buhl et al. 2011 [39] are also compar-
able to earlier unblinded results from Donohue et al. for
the comparison of indacaterol 150ug versus tiotropium.
This RCT was not included in the current study as it
was published after the search was performed and no in-
dividual patient data were available for this study at the
time of the analysis.
With a network meta-analysis, randomization only
holds within a trial and not across trials. As a result,









2 % −1.42 (−3.84; 0.97) 88 % −1.27 (−5.95; 3.74) 72 %
3 % 0.28 (−2.35; 2.97) 42 % −1.74 (−6.89; 3.54) 77 %
9 % −0.40 (−2.90; 2.07) 62 % −0.38 (−4.99; 4.87) 57 %
in 1 second; IPD = Individual patient data; SGRQ= St. George’s Respiratory
ibility to short-acting β2-agonists (SABA); reversibility to short-acting
























IPD with covariates AD with covariates
IPD without covariates AD without covariates
Figure 3 FEV1 results at 12 weeks for the individual patient and aggregate meta-analyses with and without covariates for indacaterol
75 μg versus alternative treatments. AD=Aggregate data; FOR= Formoterol 12 μg; FEV1 = Forced expiratory volume in 1 second; IND
75= Indacaterol 75 μg; IPD= Individual patient data; SAL = Salmeterol 50 μg; TIO = Tiotropium 18 μg.
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of relative treatment-effect modifiers is not similar
across trials comparing different interventions in the
network of studies, the similarity assumption and
consistency assumption in a network meta-analysis is
violated and results will be biased [17]. This bias can
be limited by adjusting for these differences by incorp-
orating treatment by covariate interactions in the stat-
istical models used.
In the current analysis the degree of heterogeneity be-
tween studies included in the AD network meta-analysis
was evaluated prior to undertaking the analysis. Dif-
ferences were identified in terms of the proportion of
males, the average age, the proportion of current smo-
kers and the proportion of patients with severe or very


























IND 75 vs. TIO
Figure 4 SGRQ total score results at 12 weeks for the individual patie
indacaterol 75 μg versus alternative treatments. AD=Aggregate data;
patient data; SAL = Salmeterol 50 μg; SGRQ= St. George Respiratory Questiothese differences using a constant treatment-by-covariate
interaction with reported average values for the patient
covariates. Although bias might be reduced, there is al-
ways the risk of residual bias with aggregate level data,
and the results might still be confounded. In this case,
since the IPD and AD results were consistent and the
IPD results with and without covariates were com-
parable; we do not expect that that the network meta-
analysis is severely biased due to violations of the
similarity or consistency assumptions. Nonetheless,
while IPD offers improvement over AD network meta-
analysis and might be considered the gold standard to
remove bias due to similarity and consistency violations,
IPD was only available for a subset of the trials and there
is always the risk of residual confounding due to covari-
ates not measured in the RCTs. Also, in the currentAD with covariates
AD without covariates
IND 75 vs. SAL IND 75 vs. FOR
nt and aggregate met-analyses with and without covariates for
FOR= Formoterol 12 μg; IND 75 = Indacaterol 75 μg; IPD= Individual
nnaire; TIO = Tiotropium 18 μg.
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ately. However, it is recommended to perform a network
meta-analysis combining the results of these six IPD
studies with other AD evidence. Recent simulations have
shown that adding IPD to AD studies in a network
meta-analysis can dramatically improve precision of the
effect estimates [5].
For the AD analyses, random effect models were
consistently presented to account for the between
study heterogeneity. However, in the case of the IPD
analyses, fixed effect models were used given the lim-
ited number of studies to estimate the between study
heterogeneity. The fixed and random effects models
had similar results as indicated by the DIC. The DIC
for the random effects model using an uninformed
prior has a slightly higher DIC than the fixed effect
model. Based on this it can be argued that the fixed
effect models are appropriate, especially given that
model diagnostics suggest the random effects model
using an uninformative prior did not converge.
The outcomes in this study are considered relevant
to treatments for COPD. FEV1 was the primary end-
point in all of the studies and is also required from a
regulatory perspective. Spirometry reflects an import-
ant prognostic factor that is used to define severity for
COPD, which is considered the most reproducible and
objective measurement of airflow limitation available
[1]. Lung function and symptoms are the worst in the
early morning and therefore affect patient functionality
and daily activities [40], while SGRQ represents a key
patient reported outcome that provides direct insight
into the overall health status of patients. Moreover, the
improvements in trough FEV1 associated with indaca-
terol 75 μg (0.13 L) relative to placebo based on the
IPD analysis can be considered clinically relevant
according to the threshold of 0.12 L pre-specified in
the RCTs [41].
Although the current network meta-analysis focused
on lung function and overall health status, identifica-
tion of the ‘best’ or most appropriate treatment can-
not be made on the basis of efficacy endpoints alone.
To inform health care decision making for clinical
treatment guidelines and reimbursement policies, the
efficacy findings must be interpreted in light of safety
profile of the compared interventions and conveni-
ence. Compared to the twice daily dosing required
for salmeterol and formoterol, the once daily regimen
for indacaterol may improve adherence in clinical
practice [42], which has been reported to range from
rates as low as 10% to 40% for COPD medication
[42–45].
In conclusion, based on a synthesis of currently avail-
able RCT evidence as well as an individual patient data
network meta-analysis of six RCTs, indacaterol 75 μg isexpected to be at least as efficacious as formoterol and
comparable to tiotropium and salmeterol regarding
FEV1. Furthermore, indacaterol 75 μg shows a compar-
able level of improvement in health-related quality of life
to tiotropium, salmeterol, and formoterol, as measured
by the SGRQ.
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